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INTRODUCTION
Glaucoma drainage devices (GDD) have been widely 
accepted in the management of refractory glaucomas.[1] 
GDDs have significantly improved the management of 
glaucoma patients but could be associated with various 
complications such as tube migration, tube or plate 
exposure or extrusion, ocular motility disturbance and 
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infection.[2] Erosion of the conjunctiva and exposure 
of GDDs remains a risk factor for the development of 
endophthalmitis.[3] Herein, we describe two cases of wound 
dehiscence and shunt displacement after subconjunctival 
bevacizumab injection as an adjunct to AGV implantation 
and report the management of this complication.
CASE REPORT
A 54‑year‑old woman was referred to Rassoul Akram 
hospital, Tehran, Iran for uncontrolled glaucoma. She had 
history of complicated cataract surgery about 20 years ago 
on the left eye and was aphakic at the time of presentation. 
Best corrected vision was 20/200, intraocular pressure 
(IOP) was 45 mmHg, cup‑to‑disc (C/D) ratio was 0.8, 
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and the superior conjunctiva was scarred from prior 
surgery. The patient was started on timolol‑dorzolamide, 
brimonidine, and latanoprost and was visited a week 
later. At that time, IOP was 30 mmHg which was not low 
enough considering the advanced glaucoma.
The patient underwent an uneventful AGV 
implantation in the superotemporal quadrant under 
general anesthesia. After preparing a fornix‑based flap, 
the AGV was primed and secured to the sclera using 
7‑0 silk sutures. The tube was inserted into the anterior 
chamber (AC) and secured by 10‑0 nylon. At the end of 
the procedure, a scleral patch graft was sutured over the 
tube using 10‑0 nylon, and the conjunctiva was closed 
using an 8‑0 Vicryl running suture. As an adjunctive 
measure, 1.25 mg (0.05 ml) bevacizumab was injected 
subconjunctivally adjacent to the AGV plate.
The day after surgery, IOP was 13, the wound was 
secure, and the tube was in a good position. The patient 
was discharged with betamethasone eye drops six times, 
and ciprofloxacin drops four times a day. Everything 
remained the same on day 4 after surgery, but on 
day 10, although IOP was 14 mmHg and visual acuity 
was stable, the patient complained of pain and copious 
discharge. On slit lamp examination, the tube was in a 
good position and the anterior chamber and vitreous were 
clear; however copious discharge was present around the 
sutures. The patient was admitted to the hospital with a 
suspected diagnosis of suture infection. Fortified topical 
vancomycin and ceftazidime were started every one hour, 
and betamethasone was discontinued. On day 3 after 
admission, anterior migration of the tube and complete 
wound dehiscence was observed [Figures 1 and 2]. For 
prevention of further complications such as tube‑corneal 
touch, the AGV was explanted and the wound was 
repaired using 10/0 nylon sutures; the GDD was sent 
to the laboratory for smears and bacterial culture which 
were negative. At the time of surgery, the scleral patch 
graft was found to be necrotic, but no sign of infection 
around the tube or plate was detected. The eye was quiet 
with no conjunctival discharge the day after surgery.
The second case was a 33‑year‑old man with history of 
congenital glaucoma. He had undergone trabeculectomy 
three times before and was pseudophakic at presentation. 
IOP was 38 mmHg with full medications, and C/D ratio 
was 0.9. He underwent uneventful AGV implantation 
and bevacizumab injection using the same technique 
described above. IOP was 12 mmHg the day after 
surgery, and the wound was secure. The patient was 
discharged on betamethasone eye drops six times a day 
and ciprofloxacin four times a day. The patient did not 
return for follow‑up until 5 months after surgery when 
was seen complaining of foreign body sensation during 
this period. Slit lamp examination revealed that the 
AGV plate was completely exposed and had migrated 
toward the limbus, but there was no sign of infection or 
inflammation. During repeat surgery, migration of the 
Figure 1. Wound dehiscence and scleral exposure in the first 
patient, 10 days after Ahmed Glaucoma Valve implantation 
with adjunctive subconjunctival bevacizumab.
Figure 2. Tube migration after Ahmed Glaucoma Valve 
implantation with adjunctive subconjunctival bevacizumab 
in the first patient.
Figure 3. Plate exposure in the second patient 5 months 
after Ahmed Glaucoma Valve implantation with adjunctive 
subconjunctival bevacizumab.
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AGV and melting of the scleral patch graft were observed 
[Figure 3]. The device was explanted and the conjunctiva 
was sutured using 10‑0 nylon.
DISCUSSION
AGV implantation is an effective surgical procedure for 
controlling refractory glaucomas.[1] Although IOP may 
successfully be controlled, conjunctival complications 
can occur after surgery. Conjunctival dehiscence is 
usually a benign complication which does not need 
repair as long as the tube is well covered. AGV tube or 
plate exposures are less common, occur later and need 
urgent repair.[4]
Reasons for conjunctival erosion over patch grafts and 
the AGV tube are not clear and the condition is probably 
multifactorial. Mechanical rubbing of the eyelid margin 
against the patch graft, excessive conjunctival tension 
over the device, tube malposition, lack of a smooth 
tapered surface between the patch graft and the host with 
poor ocular lubrication, and even minute amounts of 
absolute alcohol retained in the donor sclera might cause 
these problems.[5] Tube exposure following conjunctival 
erosion with AGV implants appears to be a major risk 
factor for development of endophthalmitis.[3]
Black race, diabetes mellitus, use of a high number of 
glaucoma medications before shunt implantation, history 
of multiple glaucoma laser procedures, the combination 
of aqueous shunt implantation with another surgery 
and inferior location of shunt are risk factors associated 
with erosion.[6,7]
Herein, we described two patients with conjunctival 
dehiscence and AGV plate displacement after adjunctive 
subconjunctival injection of bevacizumab. Both patients 
had history of chronic use of anti‑glaucoma medications 
and glaucoma surgery. In an evaluation of 158 patients 
with AGV implantation, Geffen et al reported 8.9% plate 
or tube exposure 8 months to 4 years after surgery,[4] but 
we assume that the rapid exposure we observed in our 
patients may be related to bevacizumab injection.
The function of vascular endothelial growth factor 
(VEGF) isoforms in pathological angiogenesis and 
wound healing in the eye still remains unidentified.[6] 
Wound healing involves a complex interaction between 
humoral and cellular responses as a consequence of tissue 
injury and bleeding. VEGF is crucial for angiogenesis and 
formation of granulation tissue during wound repair and 
has been proposed to play a role in the healing response 
principally by promotion of angiogenesis. It has also been 
shown to be important in epithelialization and collagen 
deposition.[8,9]
There is mounting evidence on the role of anti‑VGEF 
agents in reducing scar formation after glaucoma 
surgery, but there is little evidence on the role of VEGF 
and its complications in shunt surgery.[10] In a prospective 
study in pediatric glaucoma, Mahdy showed that the 
adjunctive use of bevacizumab or mitomycin C during 
AGV implantation significantly enhances shunt survival, 
while bevacizumab seems to be much safer with no 
visually devastating complications.[11]
In a pilot study, Chua et al used subconjunctival 
bevacizumab with 5‑fluorouracil and compared it with 
5‑fluorouracil alone after trabeculectomy augmented 
with mitomycin. Two eyes from the 5‑FU/bevacizumab 
group experienced a bleb‑related complication within 
3 months of surgery: One case of blebitis and one 
case of suture‑related abscess with secondary blebitis. 
They recommended further evaluation of the safety 
and efficacy of bevacizumab as a modulating agent in 
glaucoma filtration surgery.[12]
There are reports on the possible role of bevacizumab 
in delaying corneal wound healing. Kim et al evaluated 
the effect of bevacizumab on the duration of corneal 
wound healing and cell growth and showed that 
application of topical bevacizumab at concentrations 
of 0, 0.5, 1.0, 1.5, 2.5, or 5 mg/mL, twice daily, to 
mechanically debrided epithelia of rabbit corneas delayed 
corneal wound healing.[13] Rojo‑Arnao et al reported 
preliminary findings of adjunctive subconjunctival 
bevacizumab (SCB) injections in patients undergoing 
AGV implantation and described less aggressive 
hypertensive period as measured by post‑massage IOP 
measurements, postoperative glaucoma medications, 
and cross‑sectional bleb area by ultrasound.[14]
We injected 1.25 mg bevacizumab into the 
subconjunctival space to improve the outcome of 
implantation, but observed wound dehiscence and 
loosening of absorbable sutures in both patients. 
Although wound dehiscence may be related to chronic 
use of medications or previous surgeries, displacement 
of the shunt plate and loosening of sutures may be 
related to bevacizumab. Since any infection at the site 
of sutures might predispose patient to endophthalmitis, 
we admitted the first case for close observation, but no 
sign of AC or vitreous reaction were detected afterward. 
Moreover, we did not find any sign of infection 
during explantation of the device and no positive 
laboratory results suggesting infection. In the second 
case, the patient complained of foreign body sensation 
long before admission, but the exact time of wound 
dehiscence remained undetermined. In both eyes, the 
conjunctiva had been sutured by Vicryl sutures, and 
we suspect that the combination of bevacizumab and 
these sutures could be a predisposing factor for wound 
dehiscence.
In summary, we have reported two cases of 
wound dehiscence after subconjunctival injection of 
bevacizumab.
Since this complication may be attributed to the 
adjunctive bevacizumab, extra caution and close 
follow‑up in addition to the use of non‑absorbable 
sutures may be advised in such cases.
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